Nanovesicle delivery to the liver via retinol binding protein and platelet-derived growth factor receptors: How targeting ligands affect biodistribution

Nanomedicine

Volumn 12, Issue 4, 2017, Pages 317-331

  Hsu, Ching Yun ^a   Chen, Chun Han ^b,c   Aljuffali, Ibrahim A ^d   Dai, You Shan ^e   Fang, Jia You ^a,c,e  

^a CHANG GUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^d KING SAUD UNIVERSITY   (Saudi Arabia)

^e CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

antibody; biodistribution; liver; nanovesicle; niosome; Vitamin A

Indexed keywords

NANOCARRIER; NIOSOME; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR ANTIBODY; PLATELET DERIVED GROWTH FACTOR RECEPTOR; RECEPTOR ANTIBODY; RETINOL; RETINOL BINDING PROTEIN; SILIBININ; UNCLASSIFIED DRUG; ANTIOXIDANT; NANOCAPSULE; SILYMARIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOIMAGING; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG TARGETING; HEPATIC STELLATE CELL; IMAGING; INTESTINE; KIDNEY; LIVER; MALE; MOLECULAR STABILITY; NANOVESICLE; NONHUMAN; RAT; SPLEEN; ANIMAL; CHEMISTRY; METABOLISM; PROCEDURES; SPRAGUE DAWLEY RAT; TISSUE DISTRIBUTION; ULTRASTRUCTURE;

ANIMALS; ANTIOXIDANTS; DRUG DELIVERY SYSTEMS; HEPATIC STELLATE CELLS; LIVER; MALE; NANOCAPSULES; RATS, SPRAGUE-DAWLEY; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; RETINOL-BINDING PROTEINS; SILYMARIN; TISSUE DISTRIBUTION;

EID: 85010426187     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm-2016-0319     Document Type: Article

References (50)

1. Lundy DJ, Chen KH, Toh EKW, Hsieh PCH. Distribution of systemically administered nanoparticles reveals a size-dependent effect immediately following cardiac ischaemia-reperfusion injury. Sci. Rep. 6, 25613 (2016).
2. Noble GT, Stefanick JF, Ashley JD, Kiziltepe T, Bilgicer B. Ligand-targeted liposome design: challenges and fundamental considerations. Trends Biotechnol. 32, 32-45 (2014).
3. Taymouri S, Taheri A. Use of nanotechnology in diagnosis and treatment of hepatic fbrosis: a review. Curr. Drug Deliv. 13, 662-672 (2016).
4. Poelstra K. Liver fbrosis in 2015: crucial steps towards an effective treatment. Nat. Rev. Gastroenterol. Hepatol. 13, 67-68 (2016).
5. Kitano M, Bloomston PM. Hepatic stellate cells and microRNAs in pathogenesis of liver fbrosis. J. Clin. Med. 5, 38 (2016).
6. Li L, Wang H, Ong ZY et al. Polymer-and lip id-based nanoparticle therapeutics for the treatment of liver diseases. Nano Today 5, 296-312 (2010).
7. Sato Y, Murase K, Kato J et al. Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specifc chaperone. Nat. Biotechnol. 26, 431-442 (2008).
8. 2 to hepatic stellate cells: two options evaluated. Pharm. Res. 24, 556-574 (2007).
9. Ernsting MJ, Murakami M, Roy A, Li SD. Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. J. Control. Release 172, 782-794 (2013).
10. Phillips MA, Gran ML, Peppas NA. Targeted nanodelivery of drugs and diagnostics. Nano Today 5, 143-159 (2010).
11. Drummond DC, Noble CO, Hayes ME, Park JW, Kirpotin DB. Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development. J. Pharm. Sci. 97, 4696-4740 (2008).
12. Mane V, Muro S. Biodistribution and endocytosis of ICAM-1-targeting antibodies versus nanocarriers in the gastrointestinal tract in mice. Int. J. Nanomed. 7, 4223-4237 (2012).
13. David S, Passirani C, Carmoy N et al. DNA nanocarriers for systemic administration: characterization and in vivo bioimaging in healthy mice. Mol. Ther. Nucleic Acids 2, e64 (2013).
14. Papademetriou IT, Garnacho C, Schuchman EH, Muro S. In vivo performance of polymer nanocarriers dually-targeted to epitopes of the same or different receptors. Biomaterials 34, 3459-3466 (2013).
15. Rohilla R, Garg T, Goyal AK, Rath G. Herbal and polymeric approaches for liver-targeting drug delivery: novel strategies and their signifcance. Drug Deliv. 23, 1645-1661 (2016).
16. Marianecci C, Di Marzio L, Rinaldi F et al. Niosomes from 80s to present: the state of the art. Adv. Colloid Interf. Sci. 205, 187-206 (2014).
17. Di Marzio L, Esposito S, Rinaldi F, Marianecci C, Carafa M. Polysorbate 20 vesicles as oral delivery system: in vitro characterization. Colloids Surf. B 104, 200-206 (2013).
18. Marianecci C, Rinaldi F, Di Marzio L et al. Interaction of pH-sensitive non-phospholipid liposomes with cellular mimetic membranes. Biomed. Microdevices 15, 299-309 (2013).
19. Vargas-Mendoza N, Madrigal-Santillán E, Morales-González Á et al. Hepatoprotective effect of silymarin. World J. Hepatol. 6, 144-149 (2014).
20. Chen CH, Chang CC, Shih TH, Aljuffali IA, Yeh TS, Fang JY. Self-nanoemulsifying drug delivery systems ameliorate the oral delivery of silymarin in rats with Roux-en-Y gastric bypass surgery. Int. J. Nanomed. 10, 2403-2416 (2015).
21. Pan TL, Wang PW, Hung CF, Aljuffali IA, Dai YS, Fang JY. The impact of retinol loading and surface charge on the hepatic delivery of lipid nanoparticles. Colloids Surf. B 141, 584-594 (2016).
22. Li M, Al-Jamal KT, Kostarelos K, Reineke J. Physiologically based pharmacokinetic modeling of nanoparticles. ACS Nano 4, 6303-6317 (2010).
23. Shi B, Fang C, Pei Y. Stealth PEG-PHDCA niosomes: effects of chain length of PEG and particle size on niosomes surface properties, in vitro drug release, phagocytic uptake, in vivo pharmacokinetics and antitumor activity. J. Pharm. Sci. 95, 1873-1887 (2006).
24. Fang CL, Wen CJ, Aljuffali IA, Sung CT, Huang CL, Fang JY. Passive targeting of phosphatiosomes increases rolipram delivery to the lungs for treatment of acute lung injury: an animal study. J. Control. Release 213, 69-78 (2015).
25. Hwang TL, Aljuffali IA, Lin CF, Chang YT, Fang JY. Cationic additives in nanosystems interact with human neutrophils to activate cytotoxicity and infammatory response: lipid nanoparticles versus polymeric nanoparticles. Int. J. Nanomed. 10, 371-385 (2015).
26. Schubert MA, Harms M, Müller-Goymann CC. Structural investigations on lipid nanoparticles containing high amounts of lecithin. Eur. J. Pharm. Sci. 27, 226-236 (2006).
27. Hsu SH, Wen CJ, Al-Suwayeh SA, Chang HW, Yen TC, Fang JY. Physicochemical characterization and in vivo bioluminescence imaging of nanostructured lipid carriers (NLCs) for targeting the brain: apomorphine as a model drug. Nanotechnology 21, 405101 (2010).
28. Chirio D, Cavalli R, Trotta F, Carlotti ME, Trotta M. Deformable liposomes containing alkylcarbonates of y-cyclodextrins for dermal applications. J. Incl. Phenom. Macrocycl. Chem. 57, 645-649 (2007).
29. Juyaprasert VB, Teeranachaideekul V, Supaperm T Effect of charged and non-ionic membrane additives on physicochemical properties and stability of niosomes. AAPS PharmSciTech 9, 851-859 (2008).
30. Waddad AY, Abbad S, Yu F et al. Formulation, characterization and pharmacokinetics of morin hydrate niosomes prepared from various non-ionic surfactants. Int. J. Pharm. 456, 446-458 (2013).
31. Hsieh PW, Wen CJ, Yu HP, Aljuffali IA, Huang YH, Fang JY. Nanostructured lipid carriers containing a high percentage of a Pluronic copolymer increase the biodistribution of novel PDE4 inhibitors for the treatment of traumatic hemorrhage. J. Biomed. Nanotechnol. 10, 1520-1535 (2014).
32. Dobrovolskaia MA, Aggarwal P, Hall JB, McNeil SE. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol. Pharm. 5, 487-495 (2008).
33. Giannitrapani L, Soresi M, Bondi ML, Montalto G, Cervello M. Nanotechnology applications for the therapy of liver fbrosis. World J. Gastroenterol. 20, 7242-7251 (2014).
34. Mishra N, Yadav NP, Rai VK et al. Effcient hepatic delivery of drugs: novel strategies and their signifcance. BioMed. Res. Int. 2013, 382184 (2013).
35. Romero EL, Morilla MJ, Regts J, Koning GA, Scherphof GL. On the mechanism of hepatic transendothelial passage of large liposomes. FEBS Lett. 448, 193-196 (1999).
36. Li D, He L, Guo H, Chen H, Shan H. Targeting activated hepatic stellate cells (aHSCs) for liver fbrosis imaging. EJNMMI Res. 5, 71 (2015).
37. Shah NB, Vercellotti GM, White JG, Fegan A, Wagner CR, Bischof JC. Blood-nanoparticle interactions and in vivo biodistribution: impact of surface PEG and ligand properties. Mol. Pharm. 9, 2146-2155 (2012).
38. Jiménez Calvente C, Sehgal A, Popov Y et al. Specifc hepatic delivery of procollagen ct1(I) small interfering RNA in lipid-like nanoparticles resolves liver fbrosis. Hepatology 62, 1285-1297 (2015).
39. Beljaars L, Weert B, Geerts A, Meijer DKF, Poelstra K. The preferential homing of a platelet derived growth factor receptor-recognizing macromolecule to fbroblast-like cells in fbrotic tissue. Biochem. Pharmacol. 66, 1307-1317 (2003).
40. Ruckmani K, Sankar V, Sivakumar M. Tissue distribution, pharmacokinetics and stability studies of zidovudine delivered by niosomes and proniosomes. J. Biomed. Nanotechnol. 6, 43-51 (2010).
41. Jia L, Zhang D, Li Z et al. Nanostructured lipid carriers for parenteral delivery of silybin: biodistribution and pharmacokinetic studies. Colloids Surf. B Biointerfaces 80, 213-218 (2010).
42. Beloqui A, Solinís MA, Delgado A, Évora C, del Pozo-Rodríguez A, Rodríguez-Gascón A. Biodistribution of nanostructured lipid carriers (NLCs) after intravenous administration to rats: infuence of technological factors. Eur. J. Pharm. Biopharm. 84, 309-314 (2013).
43. Pawar S, Shevalkar G, Vavia P. Glucosamine-anchored doxorubicin-loaded targeted nano-niosomes: pharmacokinetic, toxicity and pharmacodynamic evaluation. J. Drug Target. 24, 730-743 (2016).
44. Phillips MA, Gran ML, Peppas NA. Targeted nanodelivery of drugs and diagnostics. Nano Today 5, 143-159 (2010).
45. 2 to hepatic stellate cells: two options evaluated. Pharm. Res. 24, 566-574 (2007).
46. Smeland S, Bjerknes T, Malaba L, Eskild W, Norum KR, Blomhoff R. Tissue distribution of the receptor for plasma retinol-binding protein. Biochem. J. 305, 419-424 (1995).
47. Alapatt P, Guo F, Komanetsky SM et al. Liver retinol transporter and receptor for serum retinol-binding protein (RBP4). J. Biol. Chem. 288, 1250-1265 (2013).
48. Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat. Rev. Drug Discov. 9, 615-627 (2010).
49. Kaur IP, Bhandari R, Bhandari S, Kakkar V. Potential of solid lipid nanoparticles in brain targeting. J. Control. Release 127, 97-109 (2008).
50. Wen CJ, Yen TC, Al-Suwayeh SA, Chang HW, Fang JY. In vivo real-time fuorescence visualization and brain-targeting mechanisms of lipid nanocarriers with different fatty ester: oil ratios. Nanomedicine 6, 1545-1559 (2011).